1Arizona Cancer Evolution Center, The Biodesign Institute, Arizona State University, Tempe, Arizona. 2University of Arizona Cancer Center, Tucson, Arizona. 3University of Arizona College of Medicine, ...

or “fadra”, as a single agent was presented as a poster at the 2024 EORTC-NCI-AACR 36 th Symposium on Molecular Targets and Cancer Therapeutics (“Triple Meeting”), in Barcelona ...

during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that ...

ASTX528 is a novel small molecule CBP/p300 HAT domain inhibitor with potent in vivo activity and a favourable safety profile in preclinical species that was discovered by Astex using its proprietary ...

Molecular Targets and Cancer Therapeutics Symposium ("EORTC-NCI-AACR") to be held from October 23-25, 2024 in Barcelona, Spain. SKY-1214 is an oral RNA splicing modulator developed through the ...

inhibitors will be presented at the 36 th EORTC-NCI-AACR (ENA) Symposium on molecular targets and cancer therapeutics being held October 23-25 in Barcelona, Spain. DDR2 displays aberrant ...

The EORTC-NCI-AACR symposium is being held October 23-25, 2024, in Barcelona, Spain. “With the Phase 1 trial of AU-007 completing the dose escalation and expansion phase, we are pleased to share ...

today announced four accepted abstracts at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, in Barcelona, Spain. The data being ...

While immune checkpoint blockade (ICB) therapy has shown promising results in a small subset of colorectal cancer patients with high microsatellite instability (MSI-H), the majority of patients with ...

Where? When? Who? This year’s meeting of the American Association for Cancer Research (AACR) is taking place in Orlando (FL, USA) from the 14th to the 19th of April 2023. Headed up by this year’s ...